TY - JOUR
T1 - Alpha-synuclein research
T2 - defining strategic moves in the battle against Parkinson’s disease
AU - Oliveira, Luis M.A.
AU - Gasser, Thomas
AU - Edwards, Robert
AU - Zweckstetter, Markus
AU - Melki, Ronald
AU - Stefanis, Leonidas
AU - Lashuel, Hilal A.
AU - Sulzer, David
AU - Vekrellis, Kostas
AU - Halliday, Glenda M.
AU - Tomlinson, Julianna J.
AU - Schlossmacher, Michael
AU - Jensen, Poul Henning
AU - Schulze-Hentrich, Julia
AU - Riess, Olaf
AU - Hirst, Warren D.
AU - El-Agnaf, Omar
AU - Mollenhauer, Brit
AU - Lansbury, Peter
AU - Outeiro, Tiago F.
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.
AB - With the advent of the genetic era in Parkinson’s disease (PD) research in 1997, α-synuclein was identified as an important player in a complex neurodegenerative disease that affects >10 million people worldwide. PD has been estimated to have an economic impact of $51.9 billion in the US alone. Since the initial association with PD, hundreds of researchers have contributed to elucidating the functions of α-synuclein in normal and pathological states, and these remain critical areas for continued research. With this position paper the authors strive to achieve two goals: first, to succinctly summarize the critical features that define α-synuclein’s varied roles, as they are known today; and second, to identify the most pressing knowledge gaps and delineate a multipronged strategy for future research with the goal of enabling therapies to stop or slow disease progression in PD.
UR - https://www.scopus.com/pages/publications/85111678889
U2 - 10.1038/s41531-021-00203-9
DO - 10.1038/s41531-021-00203-9
M3 - Review article
AN - SCOPUS:85111678889
SN - 2373-8057
VL - 7
JO - npj Parkinson's Disease
JF - npj Parkinson's Disease
IS - 1
M1 - 65
ER -